Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
Background TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial. Methods 450 pre-therapeutic, formalin-fixed, paraffin-embedded core biopsies from the phase II neoadjuvant GeparSixto trial that included HER2-positive and...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
7 September 2016
|
| In: |
OncoTarget
Year: 2016, Jahrgang: 7, Heft: 42, Pages: 67686-67698 |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.11891 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.18632/oncotarget.11891 Verlag, kostenfrei, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356512/ 
|
| Verfasserangaben: | Silvia Darb-Esfahani, Carsten Denkert, Albrecht Stenzinger, Christoph Salat, Bruno Sinn, Christian Schem, Volker Endris, Peter Klare, Wolfgang Schmitt, Jens-Uwe Blohmer, Wilko Weichert, Markus Möbs, Hans Tesch, Sherko Kümmel, Peter Sinn, Christian Jackisch, Manfred Dietel, Toralf Reimer, Sherene Loi, Michael Untch, Gunter von Minckwitz, Valentina Nekljudova and Sibylle Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1564992152 | ||
| 003 | DE-627 | ||
| 005 | 20220814013724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171103s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.11891 |2 doi | |
| 035 | |a (DE-627)1564992152 | ||
| 035 | |a (DE-576)494992158 | ||
| 035 | |a (DE-599)BSZ494992158 | ||
| 035 | |a (OCoLC)1340981424 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Darb-Esfahani, Silvia |d 1976- |e VerfasserIn |0 (DE-588)104251917X |0 (DE-627)769079407 |0 (DE-576)394002709 |4 aut | |
| 245 | 1 | 0 | |a Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy |c Silvia Darb-Esfahani, Carsten Denkert, Albrecht Stenzinger, Christoph Salat, Bruno Sinn, Christian Schem, Volker Endris, Peter Klare, Wolfgang Schmitt, Jens-Uwe Blohmer, Wilko Weichert, Markus Möbs, Hans Tesch, Sherko Kümmel, Peter Sinn, Christian Jackisch, Manfred Dietel, Toralf Reimer, Sherene Loi, Michael Untch, Gunter von Minckwitz, Valentina Nekljudova and Sibylle Loibl |
| 264 | 1 | |c 7 September 2016 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.11.2017 | ||
| 520 | |a Background TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial. Methods 450 pre-therapeutic, formalin-fixed, paraffin-embedded core biopsies from the phase II neoadjuvant GeparSixto trial that included HER2-positive and triple negative breast cancer (TNBC) were subjected to Sanger sequencing of exons 5-8 of the TP53 gene. TP53 status was correlated to response to neoadjuvant anthracycline/taxane-based chemotherapy with or without carboplatin and trastuzumab/lapatinib in HER2-positive and bevacizumab in TNBC. p53 protein expression was evaluated by immunohistochemistry in the TNBC subgroup. Results Of 450 breast cancer samples 297 (66.0%) were TP53 mutant. Mutations were significantly more frequent in TNBC (74.8%) compared to HER2-positive cancers (55.4%, P < 0.0001). Neither mutations nor different mutation types and effects were associated with pCR neither in the whole study group nor in molecular subtypes (P > 0.05 each). Missense mutations tended to be associated with a better survival compared to all other types of mutations in TNBC (P = 0.093) and in HER2-positive cancers (P = 0.071). In TNBC, missense mutations were also linked to higher numbers of tumor-infiltrating lymphocytes (TILs, P = 0.028). p53 protein overexpression was also linked with imporved survival (P = 0.019). Conclusions Our study confirms high TP53 mutation rates in TNBC and HER2-positive breast cancer. Mutations did not predict the response to an intense neoadjuvant chemotherapy in these two molecular breast cancer subtypes. | ||
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Endris, Volker |e VerfasserIn |0 (DE-588)1063753686 |0 (DE-627)812590961 |0 (DE-576)422898198 |4 aut | |
| 700 | 1 | |a Sinn, Peter |d 1957- |e VerfasserIn |0 (DE-588)1022590944 |0 (DE-627)717004783 |0 (DE-576)365646342 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t OncoTarget |d [Erscheinungsort nicht ermittelbar] : Impact Journals LLC, 2010 |g 7(2016), 42, Seite 67686-67698 |h Online-Ressource |w (DE-627)63035975X |w (DE-600)2560162-3 |w (DE-576)325343764 |x 1949-2553 |7 nnas |a Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy |
| 773 | 1 | 8 | |g volume:7 |g year:2016 |g number:42 |g pages:67686-67698 |g extent:13 |a Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.11891 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356512/ |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171103 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1022590944 |a Sinn, Peter |m 1022590944:Sinn, Peter |d 910000 |d 912000 |e 910000PS1022590944 |e 912000PS1022590944 |k 0/910000/ |k 1/910000/912000/ |p 15 | ||
| 998 | |g 1063753686 |a Endris, Volker |m 1063753686:Endris, Volker |d 910000 |d 912000 |e 910000PE1063753686 |e 912000PE1063753686 |k 0/910000/ |k 1/910000/912000/ |p 7 | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 3 | ||
| 999 | |a KXP-PPN1564992152 |e 2986386849 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Silvia Darb-Esfahani, Carsten Denkert, Albrecht Stenzinger, Christoph Salat, Bruno Sinn, Christian Schem, Volker Endris, Peter Klare, Wolfgang Schmitt, Jens-Uwe Blohmer, Wilko Weichert, Markus Möbs, Hans Tesch, Sherko Kümmel, Peter Sinn, Christian Jackisch, Manfred Dietel, Toralf Reimer, Sherene Loi, Michael Untch, Gunter von Minckwitz, Valentina Nekljudova and Sibylle Loibl"]},"language":["eng"],"note":["Gesehen am 03.11.2017"],"person":[{"display":"Darb-Esfahani, Silvia","given":"Silvia","family":"Darb-Esfahani","role":"aut"},{"family":"Stenzinger","role":"aut","given":"Albrecht","display":"Stenzinger, Albrecht"},{"display":"Endris, Volker","given":"Volker","role":"aut","family":"Endris"},{"family":"Sinn","role":"aut","given":"Peter","display":"Sinn, Peter"}],"recId":"1564992152","physDesc":[{"extent":"13 S."}],"id":{"eki":["1564992152"],"doi":["10.18632/oncotarget.11891"]},"title":[{"title":"Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy","title_sort":"Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"7 September 2016"}],"relHost":[{"recId":"63035975X","origin":[{"publisher":"Impact Journals LLC","dateIssuedDisp":"2010-","dateIssuedKey":"2010","publisherPlace":"[Erscheinungsort nicht ermittelbar]"}],"title":[{"title":"OncoTarget","subtitle":"open access impact journal","title_sort":"OncoTarget"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2560162-3"],"issn":["1949-2553"],"eki":["63035975X"]},"note":["Gesehen am 16.08.2018"],"pubHistory":["1.2010,Mai -"],"language":["eng"],"part":{"year":"2016","volume":"7","issue":"42","extent":"13","pages":"67686-67698","text":"7(2016), 42, Seite 67686-67698"},"disp":"Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapyOncoTarget","type":{"bibl":"periodical","media":"Online-Ressource"}}]} | ||
| SRT | |a DARBESFAHAROLEOFTP537201 | ||